Heterologous vaccination against human tuberculosis modulates antigen‐specific CD4+T‐cell function
Open Access
- 5 June 2013
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 43 (9) , 2409-2420
Abstract
Heterologous prime‐boost strategies hold promise for vaccination against tuberculosis. However, the T‐cell characteristics required for protection are not known. We proposed that boost vaccines should induce long‐lived functional and phenotypic changes to T cells primed by Bacille Calmette Guerin (BCG) and/or natural exposure to mycobacteria. We characterized changes among specific CD4+ T cells after vaccination with the MVA85A vaccine in adults, adolescents, and children. CD4+ T cells identified with Ag85A peptide‐bearing HLA class II tetramers were characterized by flow cytometry. We also measured proliferative potential and cytokine expression of Ag85A‐specific CD4+ T cells. During the effector phase, MVA85A‐induced specific CD4+ T cells coexpressed IFN‐γ and IL‐2, skin homing integrins, and the activation marker CD38. This was followed by contraction and a transition to predominantly IL‐2‐expressing, CD45RA−CCR7+CD27+ or CD45RA+CCR7+CD27+ specific CD4+ T cells. These surface phenotypes were similar to Ag85A‐specific T cells prior to MVA85A. However, functional differences were observed postvaccination: specific proliferative capacity was markedly higher after 6–12 months than before vaccination. Our data suggest that MVA85A vaccination may modulate Ag85A‐specific CD4+ T‐cell function, resulting in greater recall potential. Importantly, surface phenotypes commonly used as proxies for memory T‐cell function did not associate with functional effects of vaccination.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01 AI083156)
- National Research Foundation
- Wellcome Trust (080929/Z/06/Z, 081122/Z/06/Z)
- Europe AID (SANTE/2006/105-066)
- NIH (RO1-AI065653, NO1-AI70022)
- Wellcome Trust-funded Clinical Infectious Disease Research Initiative (084323)
- Claude Leon Foundation Fellowship
This publication has 51 references indexed in Scilit:
- A human memory T cell subset with stem cell–like propertiesNature Medicine, 2011
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccineNature, 2011
- Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferationJournal of Immunological Methods, 2010
- Dynamic T cell migration program provides resident memory within intestinal epitheliumJournal of Experimental Medicine, 2010
- Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cellsEuropean Journal of Immunology, 2009
- Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell responseVaccine, 2009
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cellsNature Medicine, 2009
- Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South AfricaThe Journal of Infectious Diseases, 2008
- Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosisProceedings of the National Academy of Sciences, 2007
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999